Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 4, 2015, Pages 607-615

  Laterza, Lucrezia ^a   Ianiro, Gianluca ^a   Scoleri, Iolanda ^a   Landi, Rosario ^a   Bruno, Giovanni ^a   Scaldaferri, Franco ^a   Gaetani, Eleonora ^a   Campanale, Mariachiara ^a   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antibiotics; Gut microbiota; Irritable bowel syndrome; Pharmacokinetic; Rifaximin

Indexed keywords

MIDAZOLAM; ORAL CONTRACEPTIVE AGENT; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACKACHE; BACTERIAL STRAIN; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FECES MICROFLORA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATHOGENESIS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ANIMAL; DRUG INTERACTION; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; DIARRHEA; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; IRRITABLE BOWEL SYNDROME; RIFAMYCINS;

EID: 84922879531     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1007951     Document Type: Review

References (68)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
2. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303(7):G775-85
3. Dupont HL. Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets. Aliment Pharmacol Ther 2014;39(10):1033-42
4. Sommer F, Backhed F. The gut microbiota - masters of host development and physiology. Nat Rev Microbiol 2013;11(4):227-38
5. Robles Alonso V, Guarner F. Linking the gut microbiota to human health. Br J Nutr 2013;109(Suppl 2):S21-6
6. Tanaka Y, Kanazawa M, Fukudo S, et al. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil 2011;17(2):131-9
7. Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2014;12(1):36-49
8. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95(12):3503-6
9. Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006;55(3):297-303
10. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136(6):1979-88
11. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26(4):535-44
12. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 2006;101(8):1894-9; quiz 1942
13. Cremon C, Stanghellini V, Pallotti F, et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology 2014;147(1):69-77
14. Yamini D, Pimentel M. Irritable bowel syndrome and small intestinal bacterial overgrowth. J Clin Gastroenterol 2010;44(10):672-5
15. Ohman L, Simren M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013;15(5):323
16. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98(2):412-19
17. Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53(1):169-74
18. Ojetti V, Lauritano EC, Barbaro F, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 2009;5(6):675-82
19. Backhed F. Host responses to the human microbiome. Nutr Rev 2012;70(Suppl 1):S14-17
20. Gasbarrini A, Lauritano EC, Garcovich M, et al. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):111-17
21. Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145(8):557-63
22. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 2009;19(1):141-50; vii
23. Marchi E, Montecchi L, Venturini AP, et al. 4-Deoxypyrido[1',2':1,2]imidazo [5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem 1985;28(7):960-3
24. Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84
25. Jiang ZD, Ke S, Dupont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010;35(3):278-81
26. Brown EL, Xue Q, Jiang ZD, et al. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010;54(1):388-96
27. Mencarelli A, Migliorati M, Barbanti M, et al. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010;80(11):1700-7
28. Mencarelli A, Renga B, Palladino G, et al. Inhibition of NF-kappaB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol 2011;668(1-2):317-24
29. Xu D, Gao J, Gillilland M, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014;146(2):484-96; e484
30. Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebocontrolled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101(2):326-33
31. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364(1):22-32
32. Infantalino A DJ, Miller C, Rupisan I, et al. Small intestinal bacterial overgrowth (SIBO) in patients with irritable bowel syndrome (IBS); a retrospective review of symptoms following treatment (Abstract). Am J Gastroenterol 2009;104:S488-99
33. Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107(1):28-35.quiz 36
34. Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011;56(7):2067-72
35. Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011;4:43-8
36. Weinstock LB. Long-term outcome of rifaximin therapy in non-constipation irritable bowel syndrome. Dig Dis Sci 2011;56(11):3389-90
37. Lembo A, Rao SS, Schoenfeld P, et al. Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): Results of the TARGET 3 study. In: American College of Gastroenterology Annual Meeting and Postgraduate Course; Philadelphia; 2014
38. Cellai L, Cerrini S, Segre A, et al. A study of structure-activity relationships in 4-deoxypyrido[1',2'-1,2]imidazo[5,4-c] rifamycin SV derivatives by electron spectroscopy for chemical analysis and 1H NMR. Mol Pharmacol 1985;27(1):103-8
39. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(Suppl 1):36-66
40. Darkoh C, Lichtenberger LM, Ajami N, et al. Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 2010;54(9):3618-24
41. Venturini AP. Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 1983;29(1):1-3
42. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(Suppl 1):13-27
43. Cellai L, Colosimo M, Marchi E, et al. Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia 1984;3(6):373-7
44. Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14(2):51-6
45. Cottreau J, Baker SF, DuPont HL, et al. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther 2000;8(7):747-60
46. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44(8):2205-6
47. XIFAXAN (rifaximin) Tablets, 550 mg NDA 21-361 Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting and XIFAXAN Package Insert
48. Cremonini F, Lembo A. Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2012;13(3):433-40
49. Taylor DN, McKenzie R, Durbin A, et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008;52(3):1179-81
50. Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998;54(1):91-3
51. Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005;3(2):201-11
52. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107(7):991-1000
53. Pae CU, Masand PS, Ajwani N, et al. Irritable bowel syndrome in psychiatric perspectives: a comprehensive review. Int J Clin Pract 2007;61(10):1708-18
54. Masand PS, Kaplan DS, Gupta S, et al. Irritable bowel syndrome and dysthymia. Is there a relationship?. Psychosomatics 1997;38(1):63-9
55. Koo HL, Sabounchi S, Huang DB, et al. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012;5:31-41
56. Salix Pharmaceuticals, Inc. In vitro assessment of induction potential of rifaximin and rifampicin in primary human hepatocytes. In. 2010
57. Trapnell CB, Connolly M, Pentikis H, et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007;41(2):222-8
58. Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007;27(10):1361-9
59. Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007;322(1):391-8
60. Hoffman JT, Hartig C, Sonbol E, et al. Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother 2011;45(5):e25
61. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23(8):1117-25
62. Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012;142(3):473-81; e474
63. Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014;39(10):1161-8
64. Salix Pharmaceuticals Inc. A phase 2, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of three different doses (275, 550, and 1100 mg) of rifaximin administered BID for either two or four weeks in the treatment of patients with diarrhea-associated irritable bowel syndrome (RFIB2001). In. 2008
65. Gomes C, Ruiz L, Pons MJ, et al. Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates. Trans R Soc Trop Med Hyg 2013;107(9):545-9
66. Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014;12(8):1390-7; e1392
67. Maccaferri S, Vitali B, Klinder A, et al. Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 2010;65(12):2556-65
68. American Gastroenterology A. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002;123(6):2105-7